Login
$PCVX
$61.61 -$1.76 (2.78%) Live

$PCVX SEC Filings

Filed On Filing
16 Nov 2026 SCHEDULE 13G
13 Nov 2026 Form 4
12 Nov 2026 144
06 Nov 2026 SCHEDULE 13G/A
06 Nov 2026 SCHEDULE 13G/A
04 Nov 2026 Form 4: Cowan Elvia, SVP, Finance & CAO

Received 3,000 shares by exercise or conversion ($77.8K) · Sold 3,000 shares ($183K)

04 Nov 2026 Form 4: Wassil Jim, EVP, Chief Scientific Ofc, COO

Received 2,250 shares by exercise or conversion ($12K) · Sold 2,250 shares ($137K)

04 Nov 2026 10-Q
04 Nov 2026 8-K: Results of Operations and Financial Condition

VAX-31 Adult Indication: Announced Positive Topline Data from OPUS-1 Pivotal Phase 3 Trial; VAX-31 Met All Prespecified Primary Endpoints, Was Well Tolerated and Demonstrated a Safety Profile Similar to PCV20 and PCV21 Across All Ages St...

02 Nov 2026 144
02 Nov 2026 144
09 Oct 2026 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +1 more

FIRST SUPPLEMENTAL INDENTURE, dated as of October 9, 2026, between Vaxcyte, Inc., a Delaware corporation, as issuer (the “Company”), and U.S. Bank Trust Company, National Association, as trustee (the “Trustee”), to the Base Indenture (as...

08 Oct 2026 424B5
08 Oct 2026 424B5
07 Oct 2026 Form 4: Wassil Jim, EVP, Chief Scientific Ofc, COO

Received 18,000 shares by exercise or conversion ($96.3K) · Sold 18,000 shares ($1.56M)

07 Oct 2026 Form 4: Cowan Elvia, SVP, Finance & CAO

Received 19,000 shares by exercise or conversion ($492K) · Sold 19,000 shares ($1.65M)

07 Oct 2026 FWP
06 Oct 2026 305B2
06 Oct 2026 424B5
06 Oct 2026 424B5

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support